Karl Kossen

Karl Kossen, PhD

SVP Translational Science

Indalo Therapeutics


Karl Kossen is an expert in the characterization of antifibrotic drugs and biomarkers of fibrotic disease, and he is currently Senior Vice President of Translational Science at Indalo. Dr. Kossen was previously Vice President of Disease Biology at InterMune, which successfully developed pirfenidone for the treatment of IPF. Following the acquisition of InterMune by Roche in 2014, Dr. Kossen co-founded Blade Therapeutics and served as Senior Vice President of Biology. He received his B.S. in Chemistry and Cell & Molecular Biology from the University of Michigan and his Ph.D. in Biochemistry from the University of Colorado.